Capricor Therapeutics Reports Long-Term Positive Data for Duchenne Muscular Dystrophy Therapy

Capricor Therapeutics has presented encouraging five-year data from its HOPE-2 Open-Label Extension study for Deramiocel, a cell therapy for Duchenne Muscular Dystrophy. The results indicate that the treatment continued to slow disease progression over an extended period. This long-term data offers hope for patients with this severe condition, building on previously reported positive Phase 3 results.